Year 2013 / Volume 105 / Number 5
Letter to the Editor
Hepatotoxicity and insomnia secondary to ranolazine

pp. 304-305

Lorena Sancho del Val, Jesús Barrio Andrés, María Teresa Herranz Bachiller y Noelia Alcaide Suárez

Abstract
Ranolazine is an antianginal drug indicated in the complementary
symptomatic treatment of stable angina (1,2). Its mechanism
of action is unknown and it appears to be due to inhibition
of the delayed sodium current in cardiac cells, thereby reducing
the overload of intracellular calcium (1,2). Since its commercialization,
there have been no reports of elevated liver enzymes
that have required suspending treatment. We present a case of elevated transaminases with insomnia associated with ranolazine treatment.
Share Button
New comment
Comments
No comments for this article
Related articles
Citation tools
Lorena Sancho del Val, Jesús Barrio Andrés, María Teresa Herranz Bachiller y Noelia Alcaide Suárez. Hepatotoxicity and insomnia secondary to ranolazine. 304-305


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 4 visits.
This article has been downloaded 3 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology